Summary & Overview
HCPCS G8809: Rh-immunoglobulin (Rhogam) Ordered
HCPCS Level II code G8809 denotes an order for Rh-immunoglobulin (Rhogam), a prophylactic immune globulin administered to prevent Rh isoimmunization after exposure to Rh-positive blood. Nationally, accurate capture of this code supports obstetric safety protocols and appropriate immunoprophylaxis tracking, which are critical for preventing hemolytic disease of the fetus and newborn.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The coverage and billing practices for G8809 affect outpatient obstetric clinics, emergency departments, and other outpatient settings where Rh-immunoglobulin is ordered and given.
Readers will learn what the code represents clinically, which service types and sites of service typically use it, payer coverage context, and which operational elements commonly accompany the service line. The publication includes benchmarks and policy-relevant notes where available, clinical context for use of Rh-immunoglobulin, and guidance on common billing modifiers and administrative considerations. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code G8809 indicates Rh-immunoglobulin (Rhogam) ordered. This code represents an order for administration of Rh-immunoglobulin, an immune globulin product used to prevent Rh isoimmunization in Rh-negative individuals exposed to Rh-positive blood.
Service Type: Medication administration / immunoprophylaxis order
Typical Site of Service: Outpatient clinic, obstetric clinic, emergency department, or other outpatient settings where Rh-immunoglobulin is ordered and administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is a Rh-negative pregnant person at 28 weeks gestation or postpartum after delivery of an Rh-positive infant who requires administration of Rh-immunoglobulin (G8809 indicates Rh-immunoglobulin ordered). The clinical workflow begins in obstetrics: prenatal blood type and antibody screen identify an Rh-negative mother without alloimmunization. At routine prenatal visit (commonly around 28 weeks) or immediately postpartum, the provider orders Rh-immunoglobulin to prevent maternal sensitization. In the prenatal setting, the medication is prepared by the pharmacy or obtained from the clinic stock and administered intramuscularly in the deltoid or gluteal muscle by a registered nurse. Postpartum, cord blood testing confirms neonatal Rh status; if the neonate is Rh-positive, Rh-immunoglobulin is given to the mother within 72 hours. Other scenarios include administration after threatened abortion, ectopic pregnancy, chorionic villus sampling, amniocentesis, or abdominal trauma during pregnancy. Documentation includes indication, maternal blood type and antibody screen results, dose, lot number, administration site, informed consent, and any immediate adverse reaction. Typical sites of service are outpatient obstetric clinics, labor and delivery units, emergency departments, and ambulatory infusion centers.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
23 | Unusual anesthesia |